retatrutide triple agonist gip glp-1 glucagon phase 3 2025 Retatrutide, a (GLP1, GIP, glucagon), just released 2 trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished What GLP‑3 Really Is: Retatrutide

Potential side effects include nausea, constipation, and gastrointestinal discomfort, particularly during early dose escalation

Jiang explained that SUSTAIN-China showed average blood sugar was reduced by 1.4 percent to 1.7 percent with semaglutide after 30 weeks, whereas with ecnoglutide it dropped by 1.89 percent to 1.91 percent after 32 weeks (shown in the separate study)

Noria SF, Shelby RD, Atkins KD, et al

Diabetic ketoacidosis hyperglycemic hyperosmolar state

Natural flavors - Mango, peach and other flavors

The skyrocketing cost of weight-loss drugs has state Medicaid programs looking for a solution States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are searching for ways to get out from under the budgetary squeeze that took them by surprise